DK1673104T4 - Fremføring af terapeutiske forbindelser til hjernen og andre væv - Google Patents

Fremføring af terapeutiske forbindelser til hjernen og andre væv Download PDF

Info

Publication number
DK1673104T4
DK1673104T4 DK04782579.9T DK04782579T DK1673104T4 DK 1673104 T4 DK1673104 T4 DK 1673104T4 DK 04782579 T DK04782579 T DK 04782579T DK 1673104 T4 DK1673104 T4 DK 1673104T4
Authority
DK
Denmark
Prior art keywords
promotion
brain
tissues
therapeutic
connections
Prior art date
Application number
DK04782579.9T
Other languages
English (en)
Other versions
DK1673104T3 (da
Inventor
Emil D Kakkis
Original Assignee
Biomarin Pharmaceutical Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34217412&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1673104(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biomarin Pharmaceutical Inc. filed Critical Biomarin Pharmaceutical Inc.
Application granted granted Critical
Publication of DK1673104T3 publication Critical patent/DK1673104T3/da
Publication of DK1673104T4 publication Critical patent/DK1673104T4/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06008—Cerebroside-sulfatase (3.1.6.8)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/0105—Alpha-N-acetylglucosaminidase (3.2.1.50)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
DK04782579.9T 2003-08-29 2004-08-30 Fremføring af terapeutiske forbindelser til hjernen og andre væv DK1673104T4 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/651,493 US7442372B2 (en) 2003-08-29 2003-08-29 Delivery of therapeutic compounds to the brain and other tissues
PCT/US2004/028135 WO2005021064A2 (en) 2003-08-29 2004-08-30 Delivery of therapeutic compounds to the brain and other tissues

Publications (2)

Publication Number Publication Date
DK1673104T3 DK1673104T3 (da) 2014-01-20
DK1673104T4 true DK1673104T4 (da) 2022-01-17

Family

ID=34217412

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04782579.9T DK1673104T4 (da) 2003-08-29 2004-08-30 Fremføring af terapeutiske forbindelser til hjernen og andre væv

Country Status (12)

Country Link
US (5) US7442372B2 (da)
EP (1) EP1673104B2 (da)
JP (1) JP5819574B2 (da)
AU (1) AU2004268645B2 (da)
CA (1) CA2537238C (da)
CY (1) CY1114815T1 (da)
DK (1) DK1673104T4 (da)
ES (1) ES2441612T5 (da)
PL (1) PL1673104T5 (da)
PT (1) PT1673104E (da)
SI (1) SI1673104T2 (da)
WO (1) WO2005021064A2 (da)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6585971B1 (en) * 1999-11-12 2003-07-01 Harbor-Ucla Research And Education Institute Recombinant α-L-iduronidase, methods for producing and purifying the same and methods for treating disease caused by deficiencies thereof
US7723296B2 (en) * 2001-01-18 2010-05-25 Genzyme Corporation Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
US7629309B2 (en) 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US20060018882A1 (en) * 2004-06-21 2006-01-26 Kaemmerer William F Medical devices and methods for delivering compositions to cells
US7442372B2 (en) 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
US20050208090A1 (en) * 2004-03-18 2005-09-22 Medtronic, Inc. Methods and systems for treatment of neurological diseases of the central nervous system
AR059089A1 (es) 2006-01-20 2008-03-12 Genzyme Corp Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal
MX361816B (es) * 2006-02-09 2018-12-17 Genzyme Corp Suministro intraventricular lento.
US20080015546A1 (en) * 2006-07-13 2008-01-17 Casas Jesus W Methods and formulations for optimal local delivery of cell therapy via minimally invasive procedures
US8849372B2 (en) * 2006-11-22 2014-09-30 The General Hospital Corporation Method for magnetic resonance imaging using stimulus induced rotary saturation with a contrast agent
WO2008070769A1 (en) * 2006-12-06 2008-06-12 Medtronic, Inc. Intrathecal catheter
CN102978185B (zh) 2007-01-18 2015-02-11 建新公司 包含氨基氧基基团的寡糖及其轭合物
WO2008089339A2 (en) * 2007-01-18 2008-07-24 Genzyme Corporation Oligosaccharide conjugates for cellular targeting
PT3252161T (pt) * 2007-06-06 2022-02-01 Genzyme Corp Terapia genética para doenças do armazenamento lisossomal
US8114346B2 (en) * 2007-08-17 2012-02-14 The Invention Science Fund I, Llc Event-triggered ultraviolet light sterilization of surfaces
US20090048648A1 (en) * 2007-08-17 2009-02-19 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Self-sterilizing device
US8460229B2 (en) 2007-08-17 2013-06-11 The Invention Science Fund I, Llc Systems, devices, and methods including catheters having components that are actively controllable between transmissive and reflective states
US8366652B2 (en) 2007-08-17 2013-02-05 The Invention Science Fund I, Llc Systems, devices, and methods including infection-fighting and monitoring shunts
US8162924B2 (en) 2007-08-17 2012-04-24 The Invention Science Fund I, Llc System, devices, and methods including actively-controllable superoxide water generating systems
US8647292B2 (en) 2007-08-17 2014-02-11 The Invention Science Fund I, Llc Systems, devices, and methods including catheters having components that are actively controllable between two or more wettability states
US8734718B2 (en) 2007-08-17 2014-05-27 The Invention Science Fund I, Llc Systems, devices, and methods including catheters having an actively controllable therapeutic agent delivery component
US8029740B2 (en) * 2008-07-11 2011-10-04 The Invention Science Fund I, Llc Event-triggered self-sterilization of article surfaces
US8753304B2 (en) 2007-08-17 2014-06-17 The Invention Science Fund I, Llc Systems, devices, and methods including catheters having acoustically actuatable waveguide components for delivering a sterilizing stimulus to a region proximate a surface of the catheter
US8702640B2 (en) 2007-08-17 2014-04-22 The Invention Science Fund I, Llc System, devices, and methods including catheters configured to monitor and inhibit biofilm formation
US8706211B2 (en) 2007-08-17 2014-04-22 The Invention Science Fund I, Llc Systems, devices, and methods including catheters having self-cleaning surfaces
EP2192924B1 (en) * 2007-08-20 2017-10-11 Protalix Ltd. Saccharide-containing protein conjugates and uses thereof
WO2009064497A1 (en) * 2007-11-15 2009-05-22 The University Of North Carolina At Chapel Hill Prostatic acid phosphatase for the treatment of pain
ES2629853T3 (es) * 2008-05-07 2017-08-16 Biomarin Pharmaceutical Inc. Péptidos de dirección lisosómica y usos de los mismos
EP2384168B1 (en) 2008-12-04 2014-10-08 Searete LLC Actively-controllable sterilizing excitation delivery implants
US9474831B2 (en) 2008-12-04 2016-10-25 Gearbox, Llc Systems, devices, and methods including implantable devices with anti-microbial properties
US8585627B2 (en) 2008-12-04 2013-11-19 The Invention Science Fund I, Llc Systems, devices, and methods including catheters configured to monitor biofilm formation having biofilm spectral information configured as a data structure
PL2889043T3 (pl) 2008-12-16 2019-09-30 Genzyme Corporation Syntetyczne związki pośrednie do wytwarzania koniugatów oligosacharyd-białko
EP2475376B1 (en) 2009-06-17 2016-03-30 BioMarin Pharmaceutical Inc. Formulations for lysosomal enzymes
EP2470199B1 (en) * 2009-08-28 2019-05-22 Icahn School of Medicine at Mount Sinai Dose escalation enzyme replacement therapy for treating acid sphingomyelinase deficiency
US9194011B2 (en) 2009-11-17 2015-11-24 Protalix Ltd. Stabilized alpha-galactosidase and uses thereof
CA2805413A1 (en) * 2010-06-25 2011-12-29 Shire Human Genetic Therapies, Inc. Methods and compositions for cns delivery of heparan n-sulfatase
UA115649C2 (uk) * 2010-06-25 2017-12-11 Шае Хюмен Дженетік Терапіс, Інк. Способи та композиції для доставки до цнс ідуронат-2-сульфатази
NZ702801A (en) * 2010-06-25 2016-08-26 Shire Human Genetic Therapies Treatment of sanfilippo syndrome type b
WO2011163651A2 (en) * 2010-06-25 2011-12-29 Shire Human Genetic Therapies, Inc. METHODS AND COMPOSITIONS FOR CNS DELIVERY OF β-GALACTOCEREBROSIDASE
AU2011270670B2 (en) * 2010-06-25 2017-01-12 Takeda Pharmaceutical Company Limited Methods and compositions for CNS delivery of arylsulfatase A
EP2588130B1 (en) * 2010-06-25 2016-08-17 Shire Human Genetic Therapies, Inc. Cns delivery of therapeutic agents
ES2896060T3 (es) 2010-06-25 2022-02-23 Shire Human Genetic Therapies Métodos y composiciones para la administración al SNC de arilsulfatasa A
JP2012062312A (ja) * 2010-08-19 2012-03-29 Yoshikatsu Eto ハンター症候群の治療剤
RS60129B1 (sr) 2011-01-20 2020-05-29 Protalix Ltd Kompozicije alfa-galaktozidaze
CN103958676A (zh) * 2011-10-12 2014-07-30 辛那杰瓦生物制药股份有限公司 重组人naglu蛋白质及其用途
US9101678B2 (en) 2011-11-03 2015-08-11 Elwha Llc Heat-sanitization of surfaces
AU2012335890A1 (en) * 2011-11-07 2014-05-29 Shire Human Genetic Therapies, Inc. Biomarkers for Sanfilippo syndrome and uses thereof
US8486399B2 (en) * 2011-12-02 2013-07-16 Armagen Technologies, Inc. Methods and compositions for increasing arylsulfatase A activity in the CNS
EA201792099A1 (ru) 2011-12-23 2018-05-31 Шир Хьюман Дженетик Терапис, Инк. Лечение когнитивных нарушений при синдроме хантера путем интратекальной доставки идуронат-2-сульфатазы
WO2013096899A2 (en) 2011-12-23 2013-06-27 Shire Human Genetic Therapies, Inc. Stable formulations for cns delivery of arylsulfatase a
US9932565B2 (en) * 2012-07-31 2018-04-03 Bioasis Technologies, Inc. Dephosphorylated lysosomal storage disease proteins and methods of use thereof
CN107865968B (zh) 2012-08-03 2021-03-05 美国政府(由卫生和人类服务部的部长所代表) 用于治疗溶酶体贮积症的环糊精
LT3115372T (lt) 2012-11-27 2019-06-25 Biomarin Pharmaceutical Inc. Tiksliniai terapiniai lizosominio fermento sulieti baltymai ir jų panaudojimas
US20150313971A1 (en) * 2012-12-07 2015-11-05 Shire Human Genetic Therapies Methods and compositions for intrathecally administered treatment of mucupolysaccharidosis type iiia
WO2014130723A1 (en) 2013-02-20 2014-08-28 Valerion Therapeutics, Llc Methods and compositions for treatment of pompe disease
KR20160010526A (ko) * 2013-05-15 2016-01-27 리젠츠 오브 더 유니버시티 오브 미네소타 중추 신경계로의 아데노-연관 바이러스 매개 유전자 전달
EP3450557A1 (en) 2013-12-25 2019-03-06 JCR Pharmaceuticals Co., Ltd. Novel anti-transferrin receptor antibody that passes through blood-brain barrier
TWI752907B (zh) * 2015-05-08 2022-01-21 美商拜奧馬林製藥公司 用於治療cln2疾病之tpp1調配物及方法
EP3307278A4 (en) 2015-06-10 2018-06-13 Vtesse, Inc. Hydroxypropyl beta-cyclodextrin compositions and methods
JP6914193B2 (ja) 2015-06-24 2021-08-04 Ｊｃｒファーマ株式会社 Ｂｄｎｆを含む融合蛋白質
KR20250073514A (ko) 2015-06-24 2025-05-27 제이씨알 파마 가부시키가이샤 혈액뇌관문을 통과하는 항인간 트랜스페린 수용체 항체
MX2018005258A (es) 2015-11-06 2019-09-04 Biomarin Pharm Inc Ensayos basados en células para la detección de anticuerpos u otros factores que neutralizan la absorción de enzimas lisosómicas.
IL261246B2 (en) 2016-02-24 2023-03-01 Biomarin Pharm Inc Therapeutic fusion proteins targeting lysosomal enzymes, their formulations and their uses
AU2017250298B2 (en) 2016-04-15 2024-10-03 The Trustees Of The University Of Pennsylvania Gene therapy for treating mucopolysaccharidosis type II
CA3026118A1 (en) * 2016-06-02 2017-12-07 Cloudbreak Therapeutics, Llc Compositions and methods of using nintedanib for treating ocular diseases with abnormal neovascularization
KR102629418B1 (ko) 2016-06-13 2024-01-25 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 최적화된 cln1 유전자 및 발현 카세트 및 그의 용도
NZ752703A (en) 2016-12-26 2022-09-30 Japan Chem Res Novel anti-human transferrin receptor antibody capable of penetrating blood-brain barrier
CA3052936A1 (en) 2016-12-26 2018-07-05 Jcr Pharmaceuticals Co., Ltd. Fusion protein of bdnf and anti-transferrin receptor antibody
US11723865B2 (en) 2017-02-08 2023-08-15 New Hope Research Foundation, Inc. Systems and methods for enhanced distribution of a biologic agent within the brain and spinal cord
US11541005B2 (en) 2017-02-08 2023-01-03 New Hope Research Foundation, Inc. Systems and methods for enhanced distribution of a biologic agent within the brain and spinal cord
JP7449223B2 (ja) 2017-09-22 2024-03-13 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア ムコ多糖症ｉｉ型を治療するための遺伝子療法
MX2020002918A (es) 2017-10-02 2020-07-22 Denali Therapeutics Inc Proteinas de fusion que comprenden enzimas de terapia de reemplazo de enzimas.
US11730767B2 (en) 2018-02-23 2023-08-22 Regeneration Biomedical, Inc. Methods, apparatuses and systems for instilling stem cells and pharmaceuticals into the human ventricular system
US12097263B2 (en) 2018-08-02 2024-09-24 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
US20220193250A1 (en) 2018-08-02 2022-06-23 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
KR20210063370A (ko) 2018-09-19 2021-06-01 리제너레이션 바이오메디칼, 인크. Wnt-활성화 지방-유래 줄기 세포 장치, 방법 및 시스템
JP6884432B2 (ja) * 2018-12-18 2021-06-09 ノイウェイ ファルマ ゲーエムベーハー 新規薬物送達システムおよびそれを提供する方法
EP3670652A1 (en) * 2018-12-18 2020-06-24 NEUWAY Pharma GmbH Vlp for the treatment of a lysosomal storage disease
US20220023434A1 (en) 2018-12-19 2022-01-27 The Board Of Trustees Of The Leland Stanford Junior University Bifunctional Molecules for Lysosomal Targeting and Related Compositions and Methods
US11446084B2 (en) 2019-07-12 2022-09-20 Neuralink Corp. Laser drilling of pia mater
CN114828960A (zh) 2019-08-29 2022-07-29 生物马林药物股份有限公司 治疗儿童个体的cln2病的方法
US20230140216A1 (en) 2020-02-03 2023-05-04 Gain Therapeutics Sa Combination therapy for treating mps1
KR102880902B1 (ko) * 2021-01-29 2025-11-03 현대자동차주식회사 셀 기반 모빌리티 생산시스템의 운영방법
EP4291237A4 (en) * 2021-02-09 2025-01-15 Phoenix Nest Inc. Nootropic peptides for treating lysosomal storage diseases
JP2024524614A (ja) 2021-07-14 2024-07-05 ライシア セラピューティクス， インコーポレイテッド Ａｓｇｐｒ細胞表面受容体結合化合物及びコンジュゲート
KR20240160120A (ko) 2022-02-18 2024-11-08 베렌 테라퓨틱스 피.비.씨. 하이드록시프로필-베타-사이클로덱스트린의 조성물 및 이의 정제 방법
WO2025125542A1 (en) * 2023-12-15 2025-06-19 F. Hoffmann-La Roche Ag Intrathecal dosage method

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2601215A (en) 1948-03-17 1952-06-17 American Cyanamid Co Process of preparing dihydropterins
US3505329A (en) 1968-02-06 1970-04-07 Smithkline Corp Process for the synthesis of biopterin
JPS5883691A (ja) 1981-11-13 1983-05-19 Kanegafuchi Chem Ind Co Ltd １′，２′−ジアシル−（６ｒ，ｓ）−５，６，７，８−テトラヒドロ−ｌ−ビオプテリンおよびその製法
CH651755A5 (en) 1982-03-03 1985-10-15 Kanegafuchi Chemical Ind Use of pterin derivatives
JPS5925323A (ja) 1982-03-03 1984-02-09 鐘淵化学工業株式会社 プテリン誘導体からなる脳内神経伝達物質の関わる疾病の治療剤
GB8318833D0 (en) 1983-07-12 1983-08-10 Wellcome Found Chemical compounds
JPS5976086A (ja) 1982-09-20 1984-04-28 ザ　ウエルカム　フアウンデ−シヨン　リミテツド プテリジン化合物
US5196533A (en) 1983-04-11 1993-03-23 South Alabama Medical Science Foundation, Usa Cyclization of 5 amino-pyrimidines to quinoid 6,6 disubstituted dihydropteridines
US4587340A (en) 1983-09-19 1986-05-06 Burroughs Wellcome Co. Biopterin analogs
JPS60178887A (ja) 1984-02-23 1985-09-12 Kanegafuchi Chem Ind Co Ltd ５，６，７，８−テトラヒドロ−ｌ−ビオプテリンの製造法
JPS60199889A (ja) 1984-03-24 1985-10-09 Kanegafuchi Chem Ind Co Ltd ５，６，７，８−テトラヒドロ−ｌ−エリスロ−ビオプテリンの硫酸塩およびその製法
US4550109A (en) 1984-05-31 1985-10-29 The Board Of Regents, The University Of Texas System Lipoidal biopterin compounds
DE3437944A1 (de) 1984-10-17 1986-07-31 Biotest-Serum-Institut Gmbh, 6000 Frankfurt Verwendung von pterinen zur steigerung der aktivitaet von lymphokinen und anderen blutfaktoren, sowie ein diagnostisches oder therapeutisches praeparat, das pterine in kombination mit lymphokinen enthaelt
CA1262347A (en) 1985-01-28 1989-10-17 Suntory Limited Preparation process of (6r)-tetrahydro-l-biopterin
JPS61277618A (ja) 1985-06-04 1986-12-08 Suntory Ltd 自閉症治療剤
US4801575A (en) * 1986-07-30 1989-01-31 The Regents Of The University Of California Chimeric peptides for neuropeptide delivery through the blood-brain barrier
CA1334654C (en) 1987-11-30 1995-03-07 Masayasu Kurono Intermediates for synthesizing bh _and its derivatives
US6149909A (en) 1995-06-23 2000-11-21 Women's And Children's Hospital Synthetic α-L-iduronidase and genetic sequences encoding same
JP2534423B2 (ja) 1991-12-26 1996-09-18 コーネル・リサーチ・ファンデーション・インコーポレイテッド 酸化窒素の過剰生産から生じる血管失調を阻止する阻害剤
US5198547A (en) 1992-03-16 1993-03-30 South Alabama Medical Science Foundation, Usa Process for N5-formylating tetrahydropteridines
US5981194A (en) 1992-07-10 1999-11-09 University Of British Columbia Use of p97 and iron binding proteins as diagnostic and therapeutic agents
DE4308739C1 (de) 1993-03-19 1994-06-23 Henning Berlin Gmbh Pterinderivate, ihre Herstellung und ihre Verwendung
US5945452A (en) 1993-06-11 1999-08-31 The Board Of Trustees Of The Leland Stanford Junior University Treatment of vascular degenerative diseases by modulation of endogenous nitric oxide production or activity
US5502050A (en) 1993-11-29 1996-03-26 Cornell Research Foundation, Inc. Blocking utilization of tetrahydrobiopterin to block induction of nitric oxide synthesis
ATE218345T1 (de) 1994-08-05 2002-06-15 Suntory Ltd Arzneimittel gegen spinocerebellare degeneration
US5716614A (en) * 1994-08-05 1998-02-10 Molecular/Structural Biotechnologies, Inc. Method for delivering active agents to mammalian brains in a complex with eicosapentaenoic acid or docosahexaenoic acid-conjugated polycationic carrier
AU7071196A (en) 1995-09-14 1997-04-01 Croptech Development Corporation Production of lysosomal enzymes in plant-based expression systems
CA2205710A1 (en) 1996-05-20 1997-11-20 The University Of British Columbia Murine model for generalized lysosomal storage disorder and methods of making and using same
US20020076782A1 (en) 1996-07-05 2002-06-20 John P.N. Rosazza Purified nitric oxide synthase
GB9617990D0 (en) 1996-08-29 1996-10-09 Scotia Holdings Plc Treatment of pain
US6458574B1 (en) * 1996-09-12 2002-10-01 Transkaryotic Therapies, Inc. Treatment of a α-galactosidase a deficiency
US5922713A (en) 1997-06-26 1999-07-13 Werner; Ernst Inhibition of nitric oxide synthase
JP4306825B2 (ja) 1998-02-27 2009-08-05 アスビオファーマ株式会社 インスリン抵抗性が関与する血管機能異常を伴う疾患の予防または治療剤
WO1999058691A2 (en) * 1998-05-13 1999-11-18 Harbor-Ucla Recombinant (alpha)-l-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof
US6200758B1 (en) 1999-02-19 2001-03-13 New York State Office Of Mental Health Phenylalanine hydroxylase gene variants, and amino acid and pterin homeostasis, in the definition, detection, treatment and prevention of psychotic, mood and personality disorders
US6217552B1 (en) 1999-03-01 2001-04-17 Coaxia, Inc. Medical device for selective intrathecal spinal cooling in aortic surgery and spinal trauma
US6521212B1 (en) 1999-03-18 2003-02-18 United Therapeutics Corporation Method for treating peripheral vascular disease by administering benzindene prostaglandins by inhalation
WO2000056328A1 (en) 1999-03-19 2000-09-28 Enos Pharmaceuticals, Inc. Increasing cerebral bioavailability of drugs
US6642038B1 (en) 1999-09-14 2003-11-04 Genzyme Glycobiology Research Institute, Inc. GlcNAc phosphotransferase of the lysosomal targeting pathway
GB2355191A (en) 1999-10-12 2001-04-18 Laxdale Ltd Combination formulations for fatigue, head injury and strokes
US6585971B1 (en) 1999-11-12 2003-07-01 Harbor-Ucla Research And Education Institute Recombinant α-L-iduronidase, methods for producing and purifying the same and methods for treating disease caused by deficiencies thereof
US6569661B1 (en) 1999-11-12 2003-05-27 Biomarin Pharmaceutical Inc. Recombinant α-L-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof
CA2720361A1 (en) * 1999-11-12 2001-05-25 Oncolytics Biotech, Inc. Viruses for the treatment of cellular proliferative disorders
US6426208B1 (en) 1999-11-12 2002-07-30 Harbor-Ucla Research And Education Institute Recombinant α-L-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof
WO2001036603A2 (en) 1999-11-17 2001-05-25 Avigen, Inc. Recombinant adeno-associated virus virions for the treatment of lysosomal disorders
US6972124B2 (en) * 2000-05-01 2005-12-06 Biomarin Pharmaceuticals Inc. Precursor of N-acetylgalactosamine-4-sulfatase, methods of treatment using said enzyme and methods for producing and purifying said enzyme
US20020006400A1 (en) 2000-05-11 2002-01-17 Peter Lobel Recombinant human CLN2 protein and methods of its production and use
US6544994B2 (en) 2000-06-07 2003-04-08 Eprov Ag Pharmaceutical preparation for treating or preventing cardiovascular or neurological disorders by modulating of the activity of nitric oxide synthase
AU2001269923A1 (en) * 2000-06-19 2002-01-02 Genzyme Corporation Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
DK1782825T3 (da) 2000-07-18 2014-11-03 Univ Duke Behandling af glycogenlagringssygdom type II
US20050119270A1 (en) 2000-08-04 2005-06-02 Mason R. P. Synergistic effect of amlodipine and atorvastatin on aortic endothelial cell nitric oxide release
ATE426021T1 (de) 2000-08-31 2009-04-15 Asubio Pharma Co Ltd Verfahren zur herstellung von biopterinen
EP1974752B1 (en) * 2001-04-30 2012-09-26 BioMarin Pharmaceutical Inc. Subcellular targeting of therapeutic proteins
WO2002098455A2 (en) † 2001-06-07 2002-12-12 Hemebiotech A/S Production of recombinant human arylsulfatase a
US20030007961A1 (en) 2001-06-22 2003-01-09 Wilburn Michael D. Orthomolecular vitamin E derivatives
US20030072761A1 (en) † 2001-10-16 2003-04-17 Lebowitz Jonathan Methods and compositions for targeting proteins across the blood brain barrier
WO2003086452A2 (en) 2002-04-05 2003-10-23 Genzyme Corporation Methods of enhancing lysosomal storage disease therapy
US20030198620A1 (en) 2002-04-16 2003-10-23 Keiya Ozawa Method of treating amino acid metabolic disorders using recombinant adeno-associated virus virions
BR122017016940B8 (pt) 2002-04-25 2021-07-27 Transkaryotic Therapies Inc método para preparação de uma composição farmacêutica compreendendo alfa-galactosidase a
US7485314B2 (en) 2002-05-06 2009-02-03 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Induction of antigen specific immunologic tolerance
US20050142141A1 (en) 2002-11-27 2005-06-30 Pardridge William M. Delivery of enzymes to the brain
DE10260263A1 (de) 2002-12-20 2004-07-15 Biocrates Life Sciences Gmbh Verwendung von Tetrahydrobiopterinderivaten zur Behandlung und Ernährung von Patienten mit Aminosäurestoffwechselstörungen
US7855063B2 (en) 2003-04-16 2010-12-21 Yeda Research And Development Co. Ltd. Partially deglycosylated glucocerebrosidase polypeptide and crystals thereof
AU2004253471B2 (en) * 2003-06-20 2010-05-13 Raptor Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
US20050026823A1 (en) * 2003-06-20 2005-02-03 Biomarin Pharmaceutical Inc. Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
US7442372B2 (en) 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
BRPI0517088A (pt) 2004-11-17 2008-09-30 Biomarin Pharm Inc formulação de comprimido estável

Also Published As

Publication number Publication date
WO2005021064A2 (en) 2005-03-10
AU2004268645A1 (en) 2005-03-10
EP1673104A2 (en) 2006-06-28
CA2537238A1 (en) 2005-03-10
US11040088B2 (en) 2021-06-22
AU2004268645B2 (en) 2010-02-18
US20170182134A1 (en) 2017-06-29
ES2441612T5 (es) 2022-04-04
ES2441612T3 (es) 2014-02-05
US9044473B2 (en) 2015-06-02
US20150150799A1 (en) 2015-06-04
EP1673104B2 (en) 2021-10-27
US9572870B2 (en) 2017-02-21
PL1673104T5 (pl) 2023-03-06
US20090017005A1 (en) 2009-01-15
US9089566B2 (en) 2015-07-28
US20120148558A1 (en) 2012-06-14
JP5819574B2 (ja) 2015-11-24
EP1673104A4 (en) 2009-08-12
US7442372B2 (en) 2008-10-28
SI1673104T1 (sl) 2014-02-28
PL1673104T3 (pl) 2014-03-31
US20050048047A1 (en) 2005-03-03
EP1673104B1 (en) 2013-10-09
PT1673104E (pt) 2014-01-15
DK1673104T3 (da) 2014-01-20
JP2007504166A (ja) 2007-03-01
CA2537238C (en) 2015-01-06
CY1114815T1 (el) 2016-12-14
SI1673104T2 (sl) 2022-01-31
WO2005021064A3 (en) 2005-08-25

Similar Documents

Publication Publication Date Title
DK1673104T3 (da) Fremføring af terapeutiske forbindelser til hjernen og andre væv
CY2013022I1 (el) Συνθεσεις για την θεραπευτικη αγωγη γαστρεντερικων διαταραχων
DK1644021T3 (da) Fremgangsmåder og sammensætninger til behandlingen af gastrointestinale sygdomme
CY2016035I1 (el) Θεραπευτικη χρηση αντισωματων anti-cs1
DK1944322T3 (da) Behandling af TNFalfa-relaterede sygdomme
DK1663978T3 (da) Fluorsubstitueret omega-carboxyaryl-diphenylurinstof til behandling og forebyggelse af sygdomme og lidelser
IS8913A (is) Afleiður 4-tetrazólýl-4-fenýlpiperidíns til þess að meðhöndla verk
DK1678194T3 (da) Modulering af syntese og degradering af hyaluronan i behandlingen af sygdom
IS7977A (is) Samsetningar og aðferð til samsettra meðferðar
DK1917246T3 (da) Benzoquinazolinderivater og deres anvendelse til behandling af knoglesygdomme
DK1485127T3 (da) Anvendelse af midler til behandling af inflammation
DK1853271T3 (da) Fremgangsmåde og præparat til behandling af perifere vaskulære sygdomme
MA28802B1 (fr) Utilisations therapeutiques d'inhibiteurs de rtp801
DK1835924T3 (da) Behandling af parkinsons sygdom og beslægtede sygdomme under anvendelse af postpartum opnåede celler
IS8371A (is) Notkun breyttra sýklósporína til að meðhöndla HCVsjúkdóma
EP1622633A4 (en) Treatment of t-cell mediated diseases
NO20055246D0 (no) Heteroaromatisk pentasyklisk forbindelse og medisinsk anvendelse derav
IS8142A (is) Læknislyf gagnleg til meðferðar á verkjum
IS8530A (is) Meðferð á truflunum í auga þar með talinni sjóndepilsrýrnun
DE602005023172D1 (de) Hydantoinderivate zur behandlung von entzündlichen erkrankungen
DK1537096T3 (da) Derivater af dioxan-2-alkylcarbamater, fremstilling og terapeutisk anvendelse heraf
CY2015003I1 (el) Φαρμακευτικες συνθεσεις για θεραπεια καρκινου
IS2650B (is) Framleiðsla á súlfínýl asetamíði
DK1487828T3 (da) Morpholinyl-urea-derivater til anvendelse til behandling af inflammatoriske sygdomme
DK1599469T3 (da) Tetrazolderivater og fremgangsmåder til behandling af metabolismerelaterede forstyrrelser dermed